Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Dow
AstraZeneca
Colorcon
Merck
McKinsey

Last Updated: January 23, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ONABOTULINUMTOXINA

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for onabotulinumtoxina

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00439140 Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder Terminated Allergan Phase 3 2007-06-01 This study will assess the safety and efficacy of botulinum toxin Type A for the treatment of urinary incontinence overactive bladder in patients with a spinal cord injury or multiple sclerosis.
NCT00777803 NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines Completed Merz Pharmaceuticals GmbH Phase 3 2008-11-01 NT 201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), is a Botulinum toxin type A preparation free of complexing proteins (150 kiloDalton). Injected into the muscle, NT201 causes a reversible local relaxation of the injected muscle. Botulinum toxin type A is used for aesthetic treatment of mimic wrinkles and in the therapy of neurologic diseases. This study will investigate the safety and efficacy (non-inferiority) of NT 201 in comparison with OnabotulinumtoxinA (Vistabel®) in the treatment of glabellar frown lines.
NCT00910520 Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed Allergan Phase 3 2009-09-01 The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
NCT00910845 Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence Completed Allergan Phase 3 2009-09-01 The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A (onabotulinumtoxinA) in treating patients with idiopathic overactive bladder with urinary incontinence.
NCT00950664 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed Ipsen Phase 4 2009-08-01 1. to examine the non-inferiority of Dysport in the clinical efficacy and safety in comparison with Botox®, assuming a bioequivalence ratio of 2.5:1 units, in the treatment of Cervical dystonia. 2. double blind, randomised, multi center, crossover study
NCT00950664 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed Medical Research Collaborating Center, Seoul, Korea Phase 4 2009-08-01 1. to examine the non-inferiority of Dysport in the clinical efficacy and safety in comparison with Botox®, assuming a bioequivalence ratio of 2.5:1 units, in the treatment of Cervical dystonia. 2. double blind, randomised, multi center, crossover study
NCT00950664 A Study to Compare Dysport® and Botox® in the Treatment of Cervical Dystonia Completed Seoul National University Hospital Phase 4 2009-08-01 1. to examine the non-inferiority of Dysport in the clinical efficacy and safety in comparison with Botox®, assuming a bioequivalence ratio of 2.5:1 units, in the treatment of Cervical dystonia. 2. double blind, randomised, multi center, crossover study
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for onabotulinumtoxina

Condition Name

Condition Name for onabotulinumtoxina
Intervention Trials
Overactive Bladder 10
Facial Rhytides 5
Migraine Disorders 5
Urinary Incontinence 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for onabotulinumtoxina
Intervention Trials
Urinary Bladder, Overactive 13
Migraine Disorders 10
Headache 6
Urinary Incontinence 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for onabotulinumtoxina

Trials by Country

Trials by Country for onabotulinumtoxina
Location Trials
United States 153
Canada 17
Germany 13
United Kingdom 12
France 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for onabotulinumtoxina
Location Trials
California 21
New York 9
Florida 9
Tennessee 8
Missouri 8
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for onabotulinumtoxina

Clinical Trial Phase

Clinical Trial Phase for onabotulinumtoxina
Clinical Trial Phase Trials
Phase 4 22
Phase 3 20
Phase 2/Phase 3 2
[disabled in preview] 28
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for onabotulinumtoxina
Clinical Trial Phase Trials
Completed 31
Recruiting 21
Active, not recruiting 8
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for onabotulinumtoxina

Sponsor Name

Sponsor Name for onabotulinumtoxina
Sponsor Trials
Allergan 36
Cady, Roger, M.D. 3
Ipsen 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for onabotulinumtoxina
Sponsor Trials
Other 49
Industry 42
U.S. Fed 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Mallinckrodt
Baxter
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.